What good are whizzy new drugs if the world can’t afford them?
Bringing gene therapies and obesity drugs to the masses will require financial innovation too, says Steven Pearson
IN RECENT YEARS biotechnology and pharmaceutical science have produced quantum leaps that both offer great opportunity and pose great risk. Gene therapies for rare conditions and obesity drugs for larger segments of society could transform health for the better. But for that to happen, policymakers and the companies behind these new treatments need to adapt quickly to the daunting cost challenges associated with them.
More from By Invitation
Kamala Harris must define herself before Donald Trump does it for her
High on her list should be wooing older, less-educated white women, says Celinda Lake, a Democratic pollster
Indermit Gill on what China and India must do to join the rich club
First invest, then infuse foreign technology and then innovate, says the World Bank’s chief economist
Use incentives, not brute force, on the cartels, says a political scientist
Benjamin Lessing reckons they can be peacefully coerced into reducing violence
Bangladesh has achieved its second liberation, says Muhammad Yunus
The interim government’s new leader argues for releasing political prisoners and holding a free election
Margaret Hodge’s lessons from east London on countering the far right
Mainstream parties must win back white working-class voters by focusing on local issues, says the former Labour MP
The real winner of Venezuela’s election urges the regime to face facts
A peaceful transfer of power is still possible, says Edmundo González